SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-042117
Filing Date
2024-10-23
Accepted
2024-10-22 18:38:16
Documents
16
Period of Report
2024-10-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49353
2 ex3-1.htm EX-3.1 15544
3 ex4-1.htm EX-4.1 333412
4 form8-k_001.jpg GRAPHIC 8211
  Complete submission text file 0001493152-24-042117.txt   660791

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lpcn-20241022.xsd EX-101.SCH 3015
6 XBRL LABEL FILE lpcn-20241022_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE lpcn-20241022_pre.xml EX-101.PRE 24165
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3802
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 241387465
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)